Every 10-Q that Cocrystal Pharma, Inc. (COCP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow COCP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COCP filings page.
Cocrystal Pharma, Inc. is a clinical-stage antiviral drug developer focused on norovirus, influenza, coronavirus and HCV. For the six months ended June 30, 2026, it generated $330,000 of government contract revenue from a NIAID SBIR Phase I award and recorded a net loss of $5.46 million, wider than a year earlier, driven mainly by higher R&D spending on its CDI-988 norovirus/coronavirus program.
Cash and restricted cash were $2.24 million at June 30, 2026, versus $7.10 million at year-end 2025, with $4.86 million used in operating activities in the first half. Management and the auditor state that these conditions raise substantial doubt about the company’s ability to continue as a going concern, and the company expects its cash, including a subsequent $5.0 million equity investment by OPKO Health on July 31, 2026, will not fund operations for 12 months after the report date.
Pipeline updates include ongoing Phase 1b norovirus challenge work and FDA Fast Track designation for CDI-988, a pan-viral 3CL protease inhibitor, and continued development of influenza candidate CC-42344 and other broad-spectrum antivirals.
Cocrystal Pharma (COCP) reported Q3 2025 results showing a net loss of $2.049 million and operating expenses of $2.089 million, reflecting sharp year‑over‑year cost reductions. For the nine months, net loss was $6.405 million as R&D spending eased following completion of a Phase 2a influenza study and Phase 1 norovirus/coronavirus trial work.
Liquidity remains tight. Cash and restricted cash were $7.804 million as of September 30, 2025, after using $6.456 million in operating cash year‑to‑date. Management stated there is “substantial doubt” about continuing as a going concern. To bolster funds, the company raised net $4.183 million in a September 12, 2025 registered direct offering (with concurrent private warrants) and $154,000 via ATM sales. Subsequent to quarter end, insiders purchased 739,426 units for gross proceeds of $1.03 million on October 28, 2025.
Pipeline updates: Oral CC‑42344 for influenza A completed Phase 2a with favorable safety. CDI‑988 completed Phase 1 with tolerability across doses up to 1,200 mg; the FDA cleared a Phase 1b norovirus challenge study, expected to begin in the first half of 2026. The company also reported a $500,000 NIH/NIAID SBIR Phase I award.
Cocrystal Pharma, Inc. (COCP) is a clinical-stage antiviral biopharmaceutical company developing candidates for influenza, norovirus, coronavirus and HCV. The company reported a six-month net loss of $4.36 million and used $5.09 million of cash in operations through June 30, 2025. Cash and restricted cash totaled $4.84 million, total assets were $8.51 million and stockholders' equity was $5.33 million as of June 30, 2025. The company recorded a large accumulated deficit of $337.8 million (in thousands).
The filing discloses substantial doubt about the company’s ability to continue as a going concern and states current resources are not expected to be sufficient to fund operations beyond the next 12 months without additional financing. Clinical updates show MHRA authorization and ongoing analysis for the CC-42344 Phase 2a human challenge study and Phase 1 data for CDI-988 with safety/tolerability reported up to 1,200 mg. The company continues to rely on equity offerings and its ATM program for liquidity.